TCDD disrupts posterior palatogenesis and causes cleft palate

Tomohiro Yamada, Azumi Hirata, Eri Sasabe, Tomohide Yoshimura, Seiji Ohno, Naoya Kitamura, Tetsuya Yamamoto

研究成果: ジャーナルへの寄稿記事

15 引用 (Scopus)

抄録

Dioxins (e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) cause cleft palate at a high rate. A post-fusional split may contribute to the pathogenesis, and tissue fragility may be a concern. The objective of this study was to investigate the effects of TCDD on the palatal epithelium, bone and muscle, which contribute to tissue integrity. ICR mice (10-12 weeks old) were used. TCDD was administered on E12.5 at 40 mg/kg. Immunohistochemical staining for AhR, ER-α, laminin, collagen IV, osteopontin, Runx2, MyoD, and desmin were performed. Furthermore, western blot analysis for osteopontin, Runx2, MyoD, and desmin were performed to evaluate protein expression in the palatal tissue. Immunohistologically, there was little difference in the collagen IV and laminin localization in the palatal epithelium between control versus TCDD-treated mice. Runx2 and osteopontin immunoreactivity decreased in the TCDD-treated palatal bone, and MyoD and desmin decreased in the TCDD-treated palatal muscle. AhR and ER-α immunoreactivity were localized to the normal palatal bone, but ER-α was diminished in the TCDD-treated palate. On western blot analysis, Runx2, MyoD, and desmin were all downregulated in the TCDD-treated palate. TCDD may suppress palatal osteogenesis and myogenesis via AhR, and cause cleft palates via a post-fusional split mechanism, in addition to a failure of palatal fusion.

元の言語英語
ページ(範囲)1-6
ページ数6
ジャーナルJournal of Cranio-Maxillofacial Surgery
42
発行部数1
DOI
出版物ステータス出版済み - 1 1 2014
外部発表Yes

Fingerprint

Cleft Palate
Desmin
Osteopontin
Palate
Laminin
Bone and Bones
Palatal Muscles
Collagen
Epithelium
Western Blotting
Polychlorinated Dibenzodioxins
Inbred ICR Mouse
Dioxins
Muscle Development
Osteogenesis
Down-Regulation
Staining and Labeling
Muscles

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology

これを引用

Yamada, T., Hirata, A., Sasabe, E., Yoshimura, T., Ohno, S., Kitamura, N., & Yamamoto, T. (2014). TCDD disrupts posterior palatogenesis and causes cleft palate. Journal of Cranio-Maxillofacial Surgery, 42(1), 1-6. https://doi.org/10.1016/j.jcms.2013.01.024

TCDD disrupts posterior palatogenesis and causes cleft palate. / Yamada, Tomohiro; Hirata, Azumi; Sasabe, Eri; Yoshimura, Tomohide; Ohno, Seiji; Kitamura, Naoya; Yamamoto, Tetsuya.

:: Journal of Cranio-Maxillofacial Surgery, 巻 42, 番号 1, 01.01.2014, p. 1-6.

研究成果: ジャーナルへの寄稿記事

Yamada, T, Hirata, A, Sasabe, E, Yoshimura, T, Ohno, S, Kitamura, N & Yamamoto, T 2014, 'TCDD disrupts posterior palatogenesis and causes cleft palate', Journal of Cranio-Maxillofacial Surgery, 巻. 42, 番号 1, pp. 1-6. https://doi.org/10.1016/j.jcms.2013.01.024
Yamada, Tomohiro ; Hirata, Azumi ; Sasabe, Eri ; Yoshimura, Tomohide ; Ohno, Seiji ; Kitamura, Naoya ; Yamamoto, Tetsuya. / TCDD disrupts posterior palatogenesis and causes cleft palate. :: Journal of Cranio-Maxillofacial Surgery. 2014 ; 巻 42, 番号 1. pp. 1-6.
@article{aa0a1c9d2aa5406888cf620a64b9b01b,
title = "TCDD disrupts posterior palatogenesis and causes cleft palate",
abstract = "Dioxins (e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) cause cleft palate at a high rate. A post-fusional split may contribute to the pathogenesis, and tissue fragility may be a concern. The objective of this study was to investigate the effects of TCDD on the palatal epithelium, bone and muscle, which contribute to tissue integrity. ICR mice (10-12 weeks old) were used. TCDD was administered on E12.5 at 40 mg/kg. Immunohistochemical staining for AhR, ER-α, laminin, collagen IV, osteopontin, Runx2, MyoD, and desmin were performed. Furthermore, western blot analysis for osteopontin, Runx2, MyoD, and desmin were performed to evaluate protein expression in the palatal tissue. Immunohistologically, there was little difference in the collagen IV and laminin localization in the palatal epithelium between control versus TCDD-treated mice. Runx2 and osteopontin immunoreactivity decreased in the TCDD-treated palatal bone, and MyoD and desmin decreased in the TCDD-treated palatal muscle. AhR and ER-α immunoreactivity were localized to the normal palatal bone, but ER-α was diminished in the TCDD-treated palate. On western blot analysis, Runx2, MyoD, and desmin were all downregulated in the TCDD-treated palate. TCDD may suppress palatal osteogenesis and myogenesis via AhR, and cause cleft palates via a post-fusional split mechanism, in addition to a failure of palatal fusion.",
author = "Tomohiro Yamada and Azumi Hirata and Eri Sasabe and Tomohide Yoshimura and Seiji Ohno and Naoya Kitamura and Tetsuya Yamamoto",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jcms.2013.01.024",
language = "English",
volume = "42",
pages = "1--6",
journal = "Journal of Cranio-Maxillo-Facial Surgery",
issn = "1010-5182",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - TCDD disrupts posterior palatogenesis and causes cleft palate

AU - Yamada, Tomohiro

AU - Hirata, Azumi

AU - Sasabe, Eri

AU - Yoshimura, Tomohide

AU - Ohno, Seiji

AU - Kitamura, Naoya

AU - Yamamoto, Tetsuya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Dioxins (e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) cause cleft palate at a high rate. A post-fusional split may contribute to the pathogenesis, and tissue fragility may be a concern. The objective of this study was to investigate the effects of TCDD on the palatal epithelium, bone and muscle, which contribute to tissue integrity. ICR mice (10-12 weeks old) were used. TCDD was administered on E12.5 at 40 mg/kg. Immunohistochemical staining for AhR, ER-α, laminin, collagen IV, osteopontin, Runx2, MyoD, and desmin were performed. Furthermore, western blot analysis for osteopontin, Runx2, MyoD, and desmin were performed to evaluate protein expression in the palatal tissue. Immunohistologically, there was little difference in the collagen IV and laminin localization in the palatal epithelium between control versus TCDD-treated mice. Runx2 and osteopontin immunoreactivity decreased in the TCDD-treated palatal bone, and MyoD and desmin decreased in the TCDD-treated palatal muscle. AhR and ER-α immunoreactivity were localized to the normal palatal bone, but ER-α was diminished in the TCDD-treated palate. On western blot analysis, Runx2, MyoD, and desmin were all downregulated in the TCDD-treated palate. TCDD may suppress palatal osteogenesis and myogenesis via AhR, and cause cleft palates via a post-fusional split mechanism, in addition to a failure of palatal fusion.

AB - Dioxins (e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) cause cleft palate at a high rate. A post-fusional split may contribute to the pathogenesis, and tissue fragility may be a concern. The objective of this study was to investigate the effects of TCDD on the palatal epithelium, bone and muscle, which contribute to tissue integrity. ICR mice (10-12 weeks old) were used. TCDD was administered on E12.5 at 40 mg/kg. Immunohistochemical staining for AhR, ER-α, laminin, collagen IV, osteopontin, Runx2, MyoD, and desmin were performed. Furthermore, western blot analysis for osteopontin, Runx2, MyoD, and desmin were performed to evaluate protein expression in the palatal tissue. Immunohistologically, there was little difference in the collagen IV and laminin localization in the palatal epithelium between control versus TCDD-treated mice. Runx2 and osteopontin immunoreactivity decreased in the TCDD-treated palatal bone, and MyoD and desmin decreased in the TCDD-treated palatal muscle. AhR and ER-α immunoreactivity were localized to the normal palatal bone, but ER-α was diminished in the TCDD-treated palate. On western blot analysis, Runx2, MyoD, and desmin were all downregulated in the TCDD-treated palate. TCDD may suppress palatal osteogenesis and myogenesis via AhR, and cause cleft palates via a post-fusional split mechanism, in addition to a failure of palatal fusion.

UR - http://www.scopus.com/inward/record.url?scp=84890861036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890861036&partnerID=8YFLogxK

U2 - 10.1016/j.jcms.2013.01.024

DO - 10.1016/j.jcms.2013.01.024

M3 - Article

VL - 42

SP - 1

EP - 6

JO - Journal of Cranio-Maxillo-Facial Surgery

JF - Journal of Cranio-Maxillo-Facial Surgery

SN - 1010-5182

IS - 1

ER -